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Mycobacterium ulcerans, the causative agent of Buruli ul-
cers (BUs), infects and destroys human skin without alerting 
the host immune system (Demangel et al., 2009). The lack 
of inflammatory infiltrates in ulcerative lesions is a striking 
histopathological feature of BU (Guarner et al., 2003). More-
over, BU patients display systemic defects in cellular immune 
responses, such as a reduced capacity of peripheral blood 
T cells to produce cytokines upon ex vivo stimulation (Phillips 
et al., 2009). These defects are independent of the activation 
stimulus and resolve upon treatment of the disease, showing 
their association with M. ulcerans. Bacterial virulence re-
lies on the production of mycolactone, a polyketide-derived 
macrolide with ulcerative properties in the skin (George et 
al., 1999). Although bacteria remain primarily at the site of 
infection, mycolactone diffuses into mononuclear blood cells, 
LNs, and spleen (Hong et al., 2008; Sarfo et al., 2011), al-
lowing it to exert immunosuppressive effects at the systemic 
level. Intraperitoneal delivery of mycolactone protects mice 
against chemically induced skin inflammation (Guenin-Macé 
et al., 2015). It prevents peripheral blood lymphocyte hom-
ing to draining LNs and expansion upon antigenic stimula-
tion (Guenin-Macé et al., 2011). Finally, M. ulcerans strains 
deficient for mycolactone production do not induce func-
tional defects in peripheral blood T cells of infected mice 
(Hong et al., 2008). Therefore, mycolactone has the intrin-
sic capacity to block the development of innate and adaptive 
immune responses in vivo.
In vitro mycolactone blunts the capacity of immune 
cells to produce selected cytokines, chemokines, and hom-
ing receptors without inducing cellular stress or cytotoxicity 
(Hall and Simmonds, 2014). Mycolactone operates post-
transcriptionally and independently of mammalian target 
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of rapamycin (mTOR) and, as such, represents a novel type 
of natural immunosuppressor. Hall et al. (2014) showed that 
mycolactone blocks the translocation of inflammatory me-
diators (TNF and Cox2) as well as model secretory proteins 
into the ER, with subsequent degradation of these proteins 
by the ubiquitin–proteasome system. Using cell-free sys-
tems, McKenna et al. (2016) later identified the translocation 
stage that mycolactone inhibits and highlighted differences 
in mycolactone-mediated inhibition of co-translationally 
versus posttranslationally inserted Sec61 secretory substrates. 
In eukaryotes, co-translational protein translocation is initi-
ated by recognition of signal peptides or nascent polypep-
tide anchor domains by the signal recognition particle (SRP). 
The SRP then targets the ribosome-nascent polypeptide 
complex to the Sec61 translocon for insertion into the ER 
lumen (Park and Rapoport, 2012). McKenna et al. (2016) 
provided biochemical evidence that mycolactone induces a 
conformational change in the pore-forming subunit of the 
translocon, Sec61α. Although Sec61, SRP-receptor, and SRP 
are sufficient for minimal translocation to occur, accessory 
components such as Sec62/63, translocating chain-associated 
membrane protein (TRAM), translocon-associated protein 
(TRAP) complex, and binding immunoglobulin protein 
(BiP) facilitate the process. What the precise molecular target 
of mycolactone is and how mycolactone’s ability to prevent 
protein translocation connects with reduced cellular immune 
responses remained critical open questions.
rESultS and dIScuSSIon
Mycolactone targets the Sec61 translocon
Among known inhibitors of protein translocation, three have 
been formally shown to act by directly targeting Sec61α: 
the cyclic heptadepsipeptide HUN-7293/cotransin/CT8, 
decadepsipeptide decatransin, and cyanobacterial product 
apratoxin A (Garrison et al., 2005; Maifeld et al., 2011; MacK-
innon et al., 2014; Junne et al., 2015; Paatero et al., 2016). 
All of these drugs target a partially overlapping site in the 
pore-forming Sec61α subunit. However, unlike decatransin 
and apratoxin A, CT8 inhibits Sec61 in a substrate-selective 
manner. To test the hypothesis that mycolactone and CT8 
use similar mechanisms of action, we performed competi-
tive Sec61α-binding assays with a structural variant of CT8 
that covalently cross-links to Sec61α upon photoactivation 
(Fig. S1 A; MacKinnon et al., 2007, 2014). ER microsomes 
were incubated with CT7 in the presence or absence of in-
creasing amounts of mycolactone and then photolyzed and 
denatured. The presence of CT7 cross-linked to Sec61α was 
then quantitatively assessed by click chemistry and in-gel flu-
orescent scanning. Mycolactone competed dose dependently 
with CT7 for binding to Sec61α (Fig. 1 A), similarly as the 
potent cotransin analogue CT9 (Fig.  1  B and Fig. S1 A). 
Importantly, mycolactone displaced CT7 slightly more ef-
ficiently than CT9, indicating that it binds Sec61α with 
comparable or higher affinity and may share a coinciding 
binding site on Sec61α.
Mycolactone consists of a lactone ring and two 
polyketide chains branched in the north and south positions 
(Fig. S1 A). We reported previously that variant 5b lacking the 
northern side chain partially retains the immunosuppressive 
activity of mycolactone, whereas subunits lacking the southern 
or both side chains (4a and 5a, respectively) are biologically 
inert (Guenin-Macé et al., 2015). Consistently, 5b competed 
with CT7 with an ∼10-fold reduced potency, whereas 4a and 
5a showed no competitive activity (Fig. 1 C). No difference 
in ability of mycolactone to compete with CT7 for Sec61α 
binding was observed after extensive washing of microsomes 
(Fig. 1 D), indicating that mycolactone binds tightly to the 
translocon and has a slow dissociation rate.
A previous genetic screen identified several point mu-
tations in Sec61α (R66I, R66G, S82P, and M136T) that re-
duce CT8 binding without major effects on channel function 
(MacKinnon et al., 2014). Given that mycolactone and CT8 
likely have overlapping binding sites, we tested whether these 
mutations confer resistance to mycolactone. For this purpose, 
we treated HEK293-FRT cells overexpressing WT or mu-
tant Sec61α constructs with increasing concentrations of my-
colactone. The viability of cells expressing WT Sec61α was 
potently reduced by mycolactone (IC50 = 10 nM; Fig. 1 E). 
In contrast, cells expressing the R66I-, R66G-, and S82P- 
mutant alleles were highly desensitized (IC50 > 1,000 nM). 
Interestingly, these mutations cluster near the lumenal plug 
of Sec61α (Fig. S1 B), suggesting that this region forms the 
mycolactone interaction site. This finding was fully consistent 
with the observation by McKenna et al. (2016) that myco-
lactone alters protease sensitivity of Sec61α in vitro. Focus-
ing on the R66G construct, we investigated whether this 
single–amino acid mutation confers resistance to mycolac-
tone-mediated blockade of protein secretion. HEK293-FRT 
cells stably expressing WT or R66G-Sec61α were transfected 
with a secreted Gaussia luciferase construct and then sub-
jected to a 24-h mycolactone treatment that did not alter cell 
viability. Although mycolactone efficiently blocked luciferase 
secretion in cells expressing WT Sec61α (IC50 = 3 nM), cells 
expressing the R66G-Sec61α mutant proved highly resistant 
(IC50 > 1,000 nM; Fig. 1 F). In addition to providing addi-
tional evidence that mycolactone binds to Sec61α, these data 
revealed the critical importance of the Sec61α R66 residue 
for mycolactone’s inhibitory activity on protein translocation.
Mycolactone is a broad-spectrum inhibitor of Sec61
A distinguishing feature of CT8 is its ability to prevent the 
translocation of only a minor subset of Sec61 clients (Besemer 
et al., 2005; Garrison et al., 2005; Maifeld et al., 2011). To de-
termine whether mycolactone shares this property, we com-
pared the effects of mycolactone and CT8 on the production 
of known Sec61 clients by human immune cells (namely TNF 
production by monocyte-derived macrophages and IFN-γ, 
IL-2, and L-selectin production by peripheral blood-derived 
CD4+ T cells). Cotransin showed a highly variable inhibitory 
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1,050 nM; not depicted). In contrast, mycolactone prevented 
the production of all tested proteins with IC50 between 4.5 
and 12 nM, suggesting that it is a more potent and less selec-
tive Sec61 inhibitor. Next, we used global proteome analysis 
of SIL AC (stable-isotope labeling with amino acids in cell 
culture) T cells to gain a broader view of mycolactone ac-
tivity and identify the proteins impacted by Sec61 inhibition 
during T cell activation. Jurkat T cells were grown in light or 
heavy SIL AC medium for five cell divisions and then treated 
with 40 nM mycolactone or vehicle for 1 h before activation 
with PMA and ionomycin (IO) for 6  h. These conditions 
induced full cell activation, bypassing a potential inhibi-
tory effect of mycolactone on TCR expression (Boulkroun 
et al., 2010). Cells were then lysed, and equal amounts of 
light- and heavy-labeled protein extracts were mixed. 
Proteins were trypsin digested, and peptide mixtures were an-
alyzed by liquid chromatography–tandem mass spectrometry 
(MS; LC-MS/MS). The SIL AC analysis was repeated with 
reversed labeling conditions, allowing the reliable identifica-
tion and quantification of 6,503 proteins (hereafter referred 
to as identified proteins). Among these, 4,636 proteins were 
quantified in both labeling conditions. SIL AC analyses were 
performed on cell extracts, and consequently, most secreted 
proteins were not detected. Notably, 52 proteins were consis-
tently down-regulated in mycolactone-treated cells (log2 my-
colactone/control ratio <−0.5), whereas only two proteins 
(putative E3 ubiquitin–protein ligase LRRC58 and Hsp70 
chaperone HSPA1A) were up-regulated (log2 mycolactone/
control ratio >0.5; Fig. 2 A and Table S1). Fig. 2 B compares 
the distribution of mycolactone–down-regulated, identified, 
and all human proteins across the different subcellular com-
partments. In contrast to cytoplasmic and nuclear proteins, 
the incidence of plasma membrane– and ER-located pro-
teins was increased in mycolactone–down-regulated proteins, 
compared with identified proteins (Fig.  2  B), indicating a 
selective down-regulation of these proteins by mycolactone. 
A key word analysis confirmed this observation and re-
vealed an additional enrichment in glycoproteins, immuno-
globulin domain–containing proteins, and proteins involved 
in the immune response among mycolactone–down- 
regulated proteins (Fig. 2 C).
Consistent with Sec61 inhibition, 42 of the 52 my-
colactone–down-regulated proteins contained a signal 
sequence or transmembrane domain directing newly 
synthesized proteins to the translocon (Table S1). The 
mycolactone–down-regulated subset was significantly 
enriched in single-pass type I/II membrane proteins 
(Fig. 2 D), indicating that such proteins are particularly 
Figure 1. Mycolactone targets the Sec61 translocon. 
(A and B) CRMs were preincubated with increasing con-
centrations of mycolactone (Myco; A) or CT9 (B) at the 
indicated concentrations, followed by 100 nM CT7. Cova-
lent CT7/Sec61α adduct was detected using click chemis-
try between the alkyne group in CT7 and rhodamine-azide 
(TAM RA). (C) As in A but comparing the competitive activ-
ity of mycolactone to that of synthetic subunits of the in-
tact molecule. (D) CRMs were incubated with a saturating 
concentration of mycolactone (10 µM) either before (pre-) 
or after (post-) extensive washing. CT7 photo–cross-link-
ing was performed after final CRM pelleting. (E) HEK293-
FRT TRex cells stably expressing WT or mutant Sec61α 
were treated with increasing concentrations of myco-
lactone for 72  h, and cell viability was analyzed by the 
Alamar blue assay (Mean ± SEM; n = 4). (F) HEK293-FRT 
TRex cells stably expressing WT Sec61α or R66G-Sec61α 
were transfected for inducible expression of a secreted 
Gaussia luciferase and then treated with increasing con-
centrations of mycolactone for 24 h. Data are lumines-
cence values (mean ± SEM; n = 2) measured from culture 
supernatants. (A–F) Data shown are from one of two inde-
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susceptible to Sec61 inhibition by mycolactone. In con-
trast, the incidence of multipass membrane proteins was 
comparable between down-regulated proteins and iden-
tified proteins, suggesting that some multipass membrane 
proteins may bypass mycolactone-mediated blockade of 
Sec61. To test this hypothesis, mRNAs for various Sec61 
substrates were translated in a reconstituted mammalian 
translation system in the presence of canine rough micro-
somes (CRMs), [35S]methionine, and increasing concen-
trations of mycolactone. In accordance with previously 
reported in vitro translation (IVT) assays of Sec61-depen-
dent secretory and type II transmembrane protein TNF 
(Hall et al., 2014; McKenna et al., 2016), ER transloca-
tion of secreted prolactin and IFN-γ was efficiently and 
dose-dependently suppressed by mycolactone (Fig.  2 E 
and Fig. S1 C). Translocation of ER-resident BiP (also 
known as HSPA5) was also affected, confirming the SIL 
AC data (Fig.  2  E and Table S1). BiP being a critical 
mediator of Sec61-dependent translocation, its depletion 
may contribute indirectly to the defective biogenesis of 
Sec61 clients in mycolactone-exposed cells. Multipass 
membrane proteins mucolipin 1 (Mcln) and a synthetic 
multipass membrane protein derived from Escherichia 
coli leader peptidase (LEP; Lundin et al., 2008) were also 
susceptible to mycolactone in IVT assays. In contrast, the 
multipass ER membrane protein CIG30 (Monné et al., 
1999) was consistently resistant to mycolactone concen-
trations up to 1 µM (Fig. 2 E and Fig. S1 C). The SIL AC 
and in vitro assays of protein translocation are thus fully 
consistent with mycolactone being a broad-acting in-
hibitor of Sec61 client production, with a more selective 
activity on multipass membrane proteins.
Figure 2. Mycolactone is a broad-spec-
trum inhibitor of Sec61. (A) Scatter plot 
showing the log2 SIL AC ratios for individual 
proteins quantified in analysis 1 on the x axis 
(light condition: 40 nM mycolactone [Myco]; 
heavy condition: vehicle control [Ctrl]) and 
analysis 2 on the y axis (reversed conditions). 
Proteins with a log2 ratio <−0.5 (pink square) 
or >0.5 (blue square) in both analyses were 
considered modulated by mycolactone. CRT 
AM, cytotoxic and regulatory T cell molecule. 
(B and C) Gene ontology cellular component 
(B) and SwissProt Protein Information resource 
keywords (C) annotation analyses of the pro-
teins that were reproducibly down-regulated 
in mycolactone-exposed T cells (red; n = 52), 
compared with identified proteins (blue; n = 
6,503) and all human proteins in UniProt (gray; 
n = 20,204). (D) Distribution of downregulated 
(red), identified (blue), and all human proteins 
(gray) over different categories of membrane 
proteins. (B–D) Statistics were calculated by 
Fisher exact tests comparing downregulated 
versus identified proteins. ***, P < 0.001. (E) IVT 
assays of various Sec61 clients in the presence 
of increasing concentrations of mycolactone. 
ER translocation of nonglycosylated proteins 
(prolactin, IFN-γ, and BiP) was assessed by 
treatment with proteinase K (PK), with resis-
tance to proteinase K indicating correct trans-
location into the ER lumen. Detergent-treated 
controls are shown in Fig. S1 C. It should be 
noted that BiP is largely protease resistant 
and, upon proteinase K treatment, forms 
shorter fragments. Translocation of glyco-
sylated proteins (Mcln, LEP, and CIG30) was 
assessed by analyzing the change in migration 
in SDS-PAGE and autoradiography. Glycosi-
dase-treated controls are shown in Fig. S1 C. 
The data shown are from one of two indepen-
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Sec61 blockade affects IFn-γ signaling in Jurkat t cells
Among the 52 proteins found to be down-regulated by 
mycolactone in PMA/IO-stimulated Jurkat T cells, 10 did 
not contain a signal sequence or transmembrane domain 
identifying them as a Sec61 client (Table S1). They were all 
encoded by IFN-stimulated genes (nine by IFN-γ and one by 
IFN-α), leading us to examine the effects of mycolactone on 
both the production of IFNs and the cell’s response to exog-
enous IFNs. Consistent with a previous study, exposing Jurkat 
T cells to mycolactone for 1 h before PMA/IO activation 
efficiently prevented IFN-γ production (Fig. 3 A), despite ro-
bust IFNG mRNA induction (Fig. 3 B; Phillips et al., 2009). 
Moreover, mycolactone-treated cells rapidly lost the ability to 
respond to IFN-γ: T cells exposed to mycolactone for >20 
min before 20-min stimulation with IFN-γ showed reduced 
STAT1 phosphorylation (Fig.  3  C). The IFN-γ receptor 
(IFN GR) was not detected by our SIL AC analysis, likely be-
cause protein level was below the detection limit. Yet, using 
flow cytometry, we found that a 6-h exposure to mycolac-
tone led to a 60% reduction in T cell surface expression of 
IFN GR1 (Fig. 3 D). Because the level of IFN GR1 transcripts 
was not altered in mycolactone-treated cells (Fig. 3 E), the 
loss of IFN GR1 likely results from Sec61 blockade. We con-
clude that both the reduced IFN-γ production and the loss of 
IFN GR1 impair the IFN-γ autocrine loop in PMA/IO- 
activated T cells exposed to mycolactone. This was further 
indicated by the reduced accumulation of IFN-γ–inducible 
GBP2 at the mRNA level (Fig.  3  F) and a Western blot 
analysis validating our SIL AC observation that mycolactone 
down-regulates GBP2 protein levels in activated Jurkat T cells 
(Fig. 3 G and Table S1). We also measured T cell responses to 
IFN-α. In Jurkat T cells exposed for 6 h to mycolactone, the 
surface level of the type I IFN receptor subunits (IFN AR1 and 
IFN AR2) was also reduced but to a lesser extent than IFN 
GR1 (Fig. 3 D). Consistently, phosphorylation of STAT1/3 
was barely affected in T cells exposed to mycolactone for 6 h 
and then pulsed with IFN-α for 20 min. However, after a 24-h 
exposure, IFN-α signaling declined considerably (Fig. 3 H). 
Altogether, our SIL AC data show that the magnitude and ki-
netics of mycolactone effects vary between Sec61 substrates, 
likely reflecting differences in protein turnover rates.
the r66G mutation in Sec61α confers broad 
resistance to mycolactone
Production of IFN-γ by T cells and IFN-γ–driven expression 
of inducible nitric oxide synthase (iNOS) in infected mac-
rophages are both essential for control of mycobacterial in-
fection (Flynn and Chan, 2001). M. ulcerans is no exception, 
as shown by the reduced capacity of IFN-γ knockout mice 
to kill intracellular bacilli during the early intramacrophage 
growth phase of the bacteria (Bieri et al., 2016). To evalu-
ate the contribution of Sec61 to mycolactone virulence, we 
examined whether mycolactone-resistant Sec61 mutants res-
cued the generation of antimycobacterial immune responses. 
Primary T cells isolated from mouse lymphoid organs were 
transduced with retroviral vectors for overexpression of WT 
Sec61α or R66G-Sec61α and fluorescent reporter protein Zs-
green (Fig. 4 A). Nontransduced and WT Sec61α–transduced 
cells were equally susceptible to mycolactone treatment, as 
demonstrated by the comparable inhibition of CD4 expres-
sion in mycolactone-exposed Zsgreen+ and Zsgreen− cells 
(Fig. 4 B). Strikingly, expression of R66G-Sec61α conferred 
resistance to mycolactone-induced defects in CD4 expres-
sion (Fig.  4  B). We reported previously that mycolactone 
efficiently down-regulates the expression of CD62L at the 
surface of naive T cells (Guenin-Macé et al., 2011). Similar to 
CD4, CD62L expression resisted mycolactone treatment in T 
cells expressing R66G-Sec61α but not WT Sec61α (Fig. 4 C). 
Further, in T cells transduced with R66G-Sec61α and stimu-
lated with PMA/IO, the production of IFN-γ was unaffected 
by mycolactone treatment (Fig. 4 D). This demonstrated that 
defects in cytokine production are also fully corrected by ex-
pression of R66G-Sec61α. A similar approach was used to 
assess the functional impact of Sec61 inhibition in macro-
phages (Fig. 4 E). Transduction of R66G-Sec61α, but not WT 
Sec61α, in bone marrow–derived macrophages conferred re-
sistance to mycolactone-mediated inhibition of IFN GR1 ex-
pression (Fig. 4 F). This reestablished the bactericidal capacity 
of macrophages, as LPS + IFN-γ–driven production of iNOS 
was restored in macrophages expressing R66G-Sec61α but 
not WT Sec61α (Fig. 4 G). Thus, by inhibiting Sec61 activity, 
mycolactone prevents both IFN-γ production by T cells and 
macrophage responsiveness to IFN-γ stimulation.
Mycolactone suppresses Sec61 activity in t cells in vivo
The data in Fig. 4 C show that CD62L expression by mouse 
primary T cells is highly susceptible to mycolactone-induced 
inhibition of Sec61. Using this membrane receptor as a read-
out, we next investigated whether systemically delivered my-
colactone impacts Sec61 activity in adoptively transferred 
T cells. Because mycolactone-induced loss of CD62L impairs 
T cell capacity to reach peripheral LNs (PLNs; Guenin-Macé 
et al., 2011), we also examined whether Sec61 blockade re-
sults in impaired homing properties. Primary T cells isolated 
from WT (C57BL/6J and CD45.2+) and congenic CD45.1 
mice were transduced with WT Sec61α or R66G-Sec61α 
(Fig.  5  A). CD45.2+ WT Sec61α–transduced cells were 
then mixed with CD45.1+ R66G-Sec61α–transduced cells 
in equal proportions and vice versa. Each mix of cells was 
then injected intravenously into WT recipient mice. Con-
comitantly, mice were given an intraperitoneal injection of 
1 mg/kg mycolactone, a treatment previously shown to in-
duce antiinflammatory effects in vivo (Guenin-Macé et al., 
2015). After 24  h, the mean surface expression of CD62L 
and the relative proportions of WT Sec61α– and R66G-
Sec61α–transduced cells in PLN and spleen were determined 
by FACS analysis. In mycolactone-injected mice, the expres-
sion of CD62L was reduced in WT Sec61α– but not R66G-
Sec61α–transduced T cells from the spleen (Fig. 5 B, left). A 
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right). This experiment demonstrated that mycolactone mod-
ulates T cell expression of CD62L in vivo in a Sec61-de-
pendent manner. Notably, R66G-Sec61α–transduced T cells 
were recovered from PLNs at significantly higher frequencies 
than WT Sec61α–transduced T cells (Fig. 5 C, right). These 
frequencies were instead comparable in the spleen, consis-
tent with CD62L not being critical for T cell homing to this 
organ (Fig. 5 C, left). Therefore, mycolactone down-regulates 
both Sec61-dependent expression of CD62L and CD62L- 
dependent lymphocyte homing in vivo.
In conclusion, we have shown that mycolactone-in-
duced Sec61 blockade is caused by a direct interaction with 
Sec61α, which determines mycolactone’s ability to prevent 
the generation of innate and adaptive immune responses. 
These data provide a molecular explanation for the immu-
nological defects of BU patients. More generally, they high-
light the critical importance of Sec61 activity for immune 
cell function, migration, and communication. Compared 
with CT8, mycolactone was more cytotoxic in human pri-
mary dermal fibroblasts and equally poorly cytotoxic in Jurkat 
T cells (Fig. S2 A). It was more effective than CT8 at inhib-
iting the production of cytokines and homing receptors by 
immune cells, and our on-going investigations suggest that 
mycolactone is also more potent than apratoxin A in these 
bioassays (not depicted). Among known inhibitors of Sec61, 
mycolactone is therefore the first produced by a human 
pathogen and likely the most potent.
Mycolactone was previously reported to bind and acti-
vate N–Wiskott–Aldrich syndrome protein (N-WASP) and 
type 2 angiotensin II receptor (AT2R) to mediate skin ulcer-
ation and analgesia, respectively (Guenin-Macé et al., 2013; 
Marion et al., 2014). Silencing of N-WASP/WASP or AT2R 
in relevant cell models did not modify the inhibitory effect 
of mycolactone on the production of secreted and membrane 
proteins (Fig. S2, B and C), showing that the immunomod-
ulatory properties of mycolactone are independent of these 
Figure 3. Mycolactone targets primarily the IFn-γ 
signaling pathway in Jurkat t cells. (A) Production of 
IFN-γ by Jurkat T cells treated with 20 nM mycolactone 
(Myco) or vehicle (Ctrl) for 6  h (Resting) or for 1  h be-
fore 6  h of activation with PMA/IO. (B) Quantitation of 
IFNG mRNAs in Jurkat T cells treated with mycolactone 
or vehicle for 6 h or for 1 h before 3 or 6 h of activa-
tion with PMA/IO. (C) Western blot analysis of tyrosine 
phosphorylated (STAT1-P) and total STAT1 in Jurkat T cells 
treated with mycolactone or vehicle for the indicated 
times before activation with 1 ng/ml IFN-γ for 20 min 
or left unstimulated (Unst). (D) Flow cytometric analysis 
of surface expression of IFN GR1, IFN AR1, and IFN AR2 by 
Jurkat T cells incubated with or without mycolactone for 
6 h. (E) Quantification of IFN GR1 mRNAs in Jurkat T cells 
treated as in B. (F and G) Quantitation of GBP2 mRNAs (F) 
and total GBP2 protein (G) in Jurkat T cells treated as in 
B. (H) Western blot analysis of phosphorylated (STAT1-P, 
STAT2-P, and STAT3-P) and total STAT1, STAT2, and STAT3 
with β-actin as the loading control in Jurkat T cells treated 
with mycolactone or vehicle for 24  h before activation 
with 1 ng/ml IFN-γ or IFN-α for 20 min or left unstimu-
lated (Unst). (A and D) Data are mean IFN-γ levels or mean 
fluorescence intensity, respectively, ± SEM of one experi-
ment performed in triplicate, relative to vehicle controls. 
(B, E, and F) Data are mean fold-changes ± SEM of one 
experiment performed in duplicate, compared with rest-
ing controls. Similar results were obtained in independent 
experiments. (A, C, G, and H) Data are from one of two 
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proteins. It is nevertheless possible that Sec61 inhibition me-
diates or at least contributes to the ulcerative and analgesic 
properties of mycolactone.
Altogether, our data reveal a novel mechanism of im-
mune evasion evolved by pathogenic mycobacteria that 
targets host cell protein translocation. Inhibition of Sec61 
activity efficiently prevented the production of key media-
tors of innate and adaptive immune responses against intra-
cellular pathogens, as we demonstrated for IFN-γ and IFN-γ 
receptor. The discovery that mycolactone inhibits Sec61 
opens novel perspectives beyond the field of inflammation. 
Because CT8 was effective at limiting proteostasis of envel-
oped viruses (Heaton et al., 2016), mycolactone may similarly 
show broad antiviral activity. It may also prove useful in the 
treatment of pathologies associated with elevated secretory 
protein synthesis. Genetically modifying Sec61 demonstrated 
the specificity of mycolactone binding to the translocon. 
Because Sec61 clients are expressed in a cell type–specific 
manner, mycolactone-mediated inhibition of protein translo-
cation into the ER could underpin the variety of its effects in 
different cell types and the distinctive features of BU.
MatErIalS and MEthodS
reagents and expression vectors
All experiments using mycolactone were done with natural 
mycolactone A/B purified from M. ulcerans bacteria (strain 
Figure 4. the r66G mutation in Sec61α confers resistance 
to mycolactone. (A) Primary mouse T cells were activated with 
anti-CD3/CD28 antibodies and then transduced with WT Sec61α or 
R66G-Sec61α before exposure to mycolactone (Myco) in resting or 
PMA/IO-stimulated conditions. (B) Differential effect of mycolactone 
(24 h at 400 nM) on the CD4 surface expression of WT Sec61α– or 
R66G-Sec61α–transduced (Zsgreen+) cells. Data are mean fluores-
cence intensity (MFI) from one of two independent experiments, 
which gave similar results. Ctrl, vehicle control; NT, nontransduced. 
(C) Dose-dependent effect of mycolactone on the CD62L sur-
face expression of WT Sec61α– or R66G-Sec61α–transduced (Zs-
green+-gated) cells. (D) Effect of a 1-h pretreatment with increasing 
doses of mycolactone on the PMA/IO-induced production of IFN-γ 
by primary T cells transduced with WT Sec61α or R66G-Sec61α 
(Zsgreen+-gated) cells. (E) Bone marrow–derived macrophages 
were transduced with WT Sec61α or R66G-Sec61α before expo-
sure to mycolactone in resting or LPS + IFN-γ–stimulated condi-
tions. (F) Dose-dependent effect of mycolactone on the IFN GR1 
surface expression of WT Sec61α– or R66G-Sec61α–transduced 
(Zsgreen+-gated) cells. (G) Dose-dependent effect of mycolactone 
on the LPS + IFN-γ–induced production of iNOS by WT Sec61α– or 
R66G-Sec61α–transduced (Zsgreen+-gated) cells. (C, D, F, and G) Data 
are mean fluorescence intensity or mean cell percentages ± SEM of 
triplicates, relative to vehicle controls. They are from one of two inde-
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1615; 35840; ATCC) and then quantified by spectrophotom-
etry (λmax = 362 nm; log ε = 4.29; Spangenberg and Kishi, 
2010). Synthetic modules of mycolactone (4a, 5a, and 5b) 
were generated as previously described (Chany et al., 2011). 
Stock solutions were prepared in either ethanol or DMSO 
and then diluted 1,000× in culture medium for cellular as-
says or 10× in PBS before injection in mice. CT7, CT8, and 
CT9 were prepared as previously described (MacKinnon 
et al., 2007; Maifeld et al., 2011). Sec61 WT or mutant se-
quences were cloned upstream of an internal ribosome entry 
site (IRES) of the pRetroX–IRES-Zsgreen retroviral vector 
(Takara Bio Inc.) for simultaneous translation of Sec61α and 
Zsgreen in mouse primary T cells and macrophages.
SdS-PaGE, autoradiography, and Western blotting
Cell lysates were resolved on NuPAGE Bis-Tris gels and 
transferred to nitrocellulose membranes (Thermo Fisher Sci-
entific). For autoradiography, dried Tris-tricine gels were ex-
posed to a storage phosphorus screen (GE Healthcare) and 
imaged on a Typhoon Trio phosphorimager (GE Healthcare). 
Protein detections used the following antibodies: WASP 
F-8 (sc-365859; Santa Cruz Biotechnology, Inc.), N-WASP 
30D10 (no. 4848; Cell Signaling Technology), pSTAT1 
Y701 (no. 9171L; Cell Signaling Technology), pSTAT2 Y689 
(no. 07-224; EMD Millipore), pSTAT3 Y705 (no. 9131L; 
Cell Signaling Technology), STAT1 (no. 06-501; EMD 
Millipore), STAT2 (06-502; EMD Millipore), STAT3 (sc-
7179; Santa Cruz Biotechnology, Inc.), AT2R (sc-9040; Santa 
Cruz Biotechnology, Inc.), β-actin (no. 3700; Cell Signaling 
Technology), GAP DH (no. 2118; Cell Signaling Technology), 
and Sec61α (NB120-15575; Novus Biologicals). Here, com-
plexes were revealed with ECL Prime detection reagent (GE 
Healthcare) and chemiluminescence reading on a lumines-
cent image analyzer (LAS-4000; Fujifilm).
Photoaffinity labeling
Protocols for CRM preparation and CT7 photoaffinity la-
beling and click chemistry were described previously (Walter 
and Blobel, 1983; MacKinnon et al., 2007). In brief, CRMs 
equivalent to 100 nM Sec61 were treated with 1 or 10 µM 
mycolactone or DMSO for 30 min at 0°C, followed by incu-
bation with 100 nM CT7 for 10 min at room temperature. 
Samples were then photolyzed for 10 min, and cross-linked 
proteins were detected by click chemistry, SDS-PAGE, and 
in-gel fluorescence scanning. In Fig. 1 D, 50 µl of photoaffin-
ity-labeling reactions were treated with 10 µM mycolactone 
on ice before (pre) or after (post-) three rounds of membrane 
pelleting. A third sample was treated after pelleting with an 
equal volume DMSO. All the samples were further incubated 
for 30 min on ice prior to CT7 photoaffinity labeling.
IVt assays
Protein translocation assays were performed as described pre-
viously (Sharma et al., 2010): DNA templates encoding the 
indicated constructs were transcribed with T7 or SP6 poly-
merase (New England Biolabs, Inc.) for 1–2 h at 37°C and 
Figure 5. Mycolactone suppresses Sec61 ac-
tivity in t cells in vivo. (A) Primary T cells isolated 
from WT (C57BL/6J and CD45.2+) and congenic 
CD45.1 mice were transduced with WT Sec61α or 
R66G-Sec61α and mixed, as depicted. Each cell 
mix was injected intravenously into four recipi-
ent mice, two of which received concomitantly an 
intraperitoneal injection of mycolactone (Myco) 
and, the other two, vehicle as control. (B) CD62L 
surface expression on WT Sec61α and R66-Sec61α 
T cells (CD45.1+ or CD45.1−; Zsgreen+ gated) recov-
ered from the spleen and PLN. Ctrl, vehicle control; 
MFI, mean fluorescence intensity. (C) Relative pro-
portion of R66G-Sec61α cells, compared with WT 
Sec61α cells, in the spleen and PLN. (B and C) Data 
are mean fluorescence intensity (B) and mean cell 
numbers (C) in each experimental group, presented 
as box and whiskers (*, P ≤ 0.05, Mann-Whitney 
test, each box corresponding to four experimental 
values). They are representative of two indepen-
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used in subsequent translation/translocation reactions. The 
reactions were assembled at 0°C in the presence of mycolac-
tone or an equivalent volume of solvent. Reactions included 
[35S]methionine (2 µCi per 10  µl translation; PerkinElmer) 
and CRM. The amount of CRM was optimized to be 0.25 µl 
per 10 µl reaction volume. Translation was initiated by trans-
ferring the reactions to 32°C for 30 or 60 min and stopped by 
returning reactions onto ice. Translocation of nonglycosylated 
proteins was assessed by treating the samples with proteinase 
K for 1 h at 0°C. An aliquot was incubated in the presence 
of TX-100 to demonstrate protection by CRMs. Proteinase 
digestion was stopped with PMSF and boiling in the presence 
of SDS. After TCA precipitation, the remaining, protected 
proteins/protein fragments were analyzed with SDS-PAGE 
and autoradiography. The translocation of glycosylated pro-
teins was analyzed by SDS-PAGE and autoradiography. Alter-
natively, the control samples were first denatured and treated 
with endoglycosidase H (EndoH) to demonstrate that differ-
ences in gel migration are based on glycosylation.
cell cultures
Jurkat T cells (E6.1 clone; no. 88042803; European Collec-
tion of Authenticated Cell Cultures [ECA CC]), HeLa cells 
(no. 93021013; ECA CC), human primary dermal fibroblasts 
(C-013-5C; Thermo Fisher Scientific), and HEK293-FRT 
TRex cells stably expressing WT or mutant Sec61α were cul-
tured in RPMI GlutaMAX (Jurkat) or DMEM GlutaMAX 
(other cells) from Thermo Fisher Scientific, supplemented 
with 10% heat-inactivated FCS (Invitrogen), 100 U/ml pen-
icillin, and 100 µg/ml streptomycin. Human primary T cells 
were isolated from blood donors by Ficoll density gradient 
centrifugation and CD4+ T cell purification by negative de-
pletion (Miltenyi Biotec). Human primary macrophages were 
obtained from peripheral blood-derived monocytes, isolated 
by adhesion to tissue culture plasticware, and cultured with 
10 ng/ml human GM-CSF (PeproTech) for 7–12 d. Mouse 
CD3+ primary T cells were isolated from spleens and LNs by 
negative selection using the Pan T cell isolation kit (Miltenyi 
Biotec) and then placed in RPMI medium supplemented 
with 10% heat-inactivated FCS, 10 mM Hepes, 1 mM pyru-
vate, and 25 µM 2-mercaptoethanol. Bone marrow–derived 
macrophages were obtained by a 7-d differentiation of mouse 
progenitors in DMEM supplemented with 20% heat-inacti-
vated horse serum (Gibco) and 30% L929-conditioned me-
dium as a source of M-CSF.
SIl ac labeling and lc-MS/MS analysis
For SIL AC labeling, Jurkat T cells were cultured in DMEM 
medium without l-lysine, l-arginine, or l-glutamine (Silantes 
Gmbh) supplemented with 10% heat-inactivated FCS (In-
vitrogen), 2  mM GlutaMAX, and either natural l-arginine 
HCl and l-lysine HCl (light labeling; Sigma-Aldrich) or [13C6]
[15N2] l-lysine HCl and [13C6]l-arginine HCl (heavy labeling; 
Silantes Gmbh). l-Lysine HCl was added at its normal con-
centration in DMEM (146 mg/L), but the concentration of 
l-arginine HCl was reduced to 30 mg/L (36% of the normal 
concentration in DMEM) to prevent metabolic conversion of 
arginine to proline. Cells were kept for at least six population 
doublings to ensure complete incorporation of the labeled 
lysine and arginine. Light (L) and heavy (H) SIL AC-labeled 
Jurkat T cells were treated with 40 nM mycolactone or vehicle 
as control for 1 h and then activated with PMA/IO for 6 h. 
Two experiments were performed in reverse labeling condi-
tions, yielding four samples. From each condition, 5 × 106 cells 
were harvested and washed twice with PBS, and cell pellets 
were frozen at −80°C until further use. Each pellet was resus-
pended in 500 µl lysis buffer (9 M urea in 20 mM Hepes, pH 
8.0), sonicated (three bursts of 15 s at an amplitude of 20%) and 
centrifuged for 15 min at 16,000 g at 4°C to remove insoluble 
material. The protein concentration in the supernatants was 
measured using a Bradford assay (Bio-Rad Laboratories), and 
equal protein amounts of mycolactone-treated and untreated 
cell lysates were mixed to obtain two replicate samples with 
reversed SIL AC for further analysis, each containing 5.6 mg 
total protein (sample 1: vehicle [H] + mycolactone [L]; sample 
2: vehicle [L] + mycolactone [H]). Proteins in each sample 
were reduced with 5 mM dithiothreitol and incubation for 
30 min at 30°C and then alkylated by addition of 100 mM 
chloroacetamide for 15 min at room temperature in the dark. 
Both samples were further diluted with 20 mM Hepes, pH 
8.0, to a final urea concentration of 2 M, and proteins were 
digested with 50 µg trypsin (1/113, wt/wt; Promega) over-
night at 37°C. Peptides were then purified on a Sep-Pak C18 
cartridge (Waters), and 500 µg of peptides of each sample was 
redissolved in 10 mM ammonium acetate, pH 5.5, in water/
acetonitrile (98/2, vol/vol) and injected on a capillary reversed 
phase high-performance liquid chromatography column 
(Zorbax 300SB-C18; 2.1 mm internal diameter and 150 mm 
length; Agilent Technologies) using a high-performance liquid 
chromatography system (1200 Series; Agilent Technologies). 
Peptides were separated by a linear gradient of acetonitrile 
(from 2% to 70% in 100 min in 10 mM ammonium acetate, 
pH 5.5), and peptides that eluted between 20 and 92 min were 
collected in 72 fractions of 1 min each. Fractions with 12-min 
difference in retention time were pooled to obtain total of 12 
fractions for LC-MS/MS per sample. Peptides in each fraction 
were dried and redissolved in 12 µl of solvent A (0.1% formic 
acid in water/acetonitrile; 98:2, vol/vol), of which 5 µl was 
injected for LC-MS/MS analysis on an Ultimate 3000 RSLC-
nano system (Thermo Fisher Scientific) in-line connected to 
a Q Exactive mass spectrometer with a Nanospray Flex Ion 
source (Thermo Fisher Scientific). Trapping was performed at 
10 µl/min for 3 min in solvent A on a PepMap C18 column 
(0.3 mm inner diameter × 5 mm; Dionex), and after back 
flushing from the trapping column, the sample was loaded on 
a reverse-phase column (made in house; 75 µm inner diam-
eter × 500 mm; 1.9 µm beads C18 Reprosil-Pur; Dr. Maisch 
GmbH). Peptides were eluted by an increase in solvent B 
(0.08% formic acid in water/acetonitrile; 2:8, vol/vol) in lin-
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40% in 150 min, and finally from 40% to 55% in 30 min, all 
at a constant flow rate of 300 nl/min. The mass spectrometer 
was operated in data-dependent mode, automatically switch-
ing between MS and MS/MS acquisition for the 15 most 
abundant ion peaks per MS spectrum. Full-scan MS spectra 
(300–2,000 m/z) were acquired at a resolution of 70,000 after 
accumulation to a target value of 1,000,000 with a maximum 
fill time of 100 ms. The 15 most intense ions above a threshold 
value of 100,000 were isolated (window of 2.5 Th) for frag-
mentation by collision-induced dissociation at a normalized 
collision energy of 27% after filling the trap at a target value 
of 100,000 for a maximum of 160 ms with an underfill ratio 
of 0.1%. The S-lens radio frequency level was set at 55, and we 
excluded precursor ions with single, unassigned, and charge 
states above six from fragmentation selection.
data processing and gene ontology 
terms enrichment analysis
Data analysis was performed with MaxQuant software (version 
1.4.1.2; Cox and Mann, 2008) using the Andromeda search 
engine (Cox et al., 2011) with default search settings including 
a false discovery rate set at 1% on both the peptide and protein 
levels. Spectra were searched against the human proteins in the 
UniProt/SwissProt database (database release version of Janu-
ary 2014 containing 20,272 human protein sequences) with a 
mass tolerance for precursor and fragment ions of 4.5 and 20 
ppm, respectively, during the main search. To enable the iden-
tification of SIL AC-labeled peptides, the multiplicity was set to 
two with Lys8 and Arg6 settings in the heavy channel, allowing 
for a maximum of three labeled amino acids per peptide. En-
zyme specificity was set as C-terminal to arginine and lysine, 
also allowing cleavage at proline bonds and a maximum of two 
missed cleavages. Variable modifications were set to oxidation 
of methionine residues and acetylation of protein N termini. 
Carbamidomethyl formation of cysteine residues was set as a 
fixed modification. In total, 6,503 proteins were identified in 
both samples, of which 4,636 proteins were quantified. For each 
quantified protein, the log2 values of the normalized mycolac-
tone/untreated ratio in both samples were plotted against each 
other to generate the scatter plot depicted in Fig. 2 and Table 
S1. Proteins with log2 (mycolactone/untreated ratios) <−0.5 
in both samples were considered as specific mycolactone tar-
gets that are down-regulated upon treatment. Proteomic data 
were deposited to the ProteomeXchange Consortium via the 
PRI DE partner repository under accession no. PXD002971. 
Gene Ontology and SwissProt Protein Information resource 
terms enrichment analyses were performed using Database for 
Annotation, Visualization and Integrated Discovery (DAV ID) 
bioinformatics resources (Huang et al., 2009). Information on 
the topology of membrane proteins were retrieved from the 
UniProt/SwissProt database.
Flow cytometry
Staining of mouse cells was performed using anti-CD4 (no. 
553051; BD), anti-CD62L (l-selectin; no. 553162; BD), 
anti-CD3 (no. 553064; BD), anti-CD19 (no. 550992; BD), 
anti-CD45.1 (no. 5061788; BD), anti-IFN GR1 (130-104-
988; Miltenyi Biotec), anti–IFN-γ (no. 554412; BD), and 
anti–IL-2 (no. 554429; BD). For intracellular staining of cy-
tokines, cells were treated with mycolactone for 1 h and then 
activated with PMA/IO. GolgiStop (BD) was added 2 h later. 
After 6 h, cells were fixed with 4% (wt/vol) paraformalde-
hyde during 20 min at room temperature and then stained 
with PE-conjugated anti–IFN-γ antibodies (BD) in 100 µl 
PBS + 0.1% BSA + 0.5% saponin for 30 min at room tem-
perature. For intracellular staining of iNOS, macrophages 
were fixed with Lyse/Fix solution (no. 558049; BD) for 10 
min at 37°C and then permeabilized with Perm Buffer III 
(no. 558050; BD) for 20 min at 4°C. Staining was performed 
with goat anti-NOS2 (sc-650-G; Santa Cruz Biotechnology, 
Inc.) followed by an anti–goat secondary antibody (no. 96938; 
Abcam). Staining of Jurkat was performed using anti-IFN GR1 
(no. 558937; BD), IFN AR1 (no. 550331; BD), and IFN AR2 
(no. 1080-08; SouthernBiotech). In brief, human cells were 
stained with IFN AR1 or IFN AR2, washed twice with PBS, 
incubated with biotin-conjugated rat anti–mouse IgG (no. 
415-065-166; Jackson ImmunoResearch Laboratories, Inc.), 
washed, and then incubated with R-PE–conjugated strepta-
vidin (PNIM0557; Beckman Coulter). All FACS acquisition 
was performed on a FACS Accuri C6 flow cytometer (BD), 
and data were analyzed using FlowJo software (Tree Star).
retroviral transduction
Platinum-E ecotropic packaging cells (plat E; Biolabs) trans-
fected with pRetroX–IRES-Zsgreen plasmids containing 
Sec61α sequences were used to produce retroviral particles. 
Immediately after isolation from mouse organs, CD3+ T cells 
were activated with Dynabeads Mouse T-activator CD3/
CD28 (Miltenyi Biotec) with 1 bead/cell in RPMI medium 
supplemented with 10% heat-inactivated FCS, 10 mM Hepes, 
1 mM pyruvate, and 25 µM 2-mercaptoethanol (complete me-
dium). 24 h later, cells were centrifuged at 1,200 rpm, and the 
supernatant (conditioned medium) was saved. Cells were resus-
pended at 4 × 106 cells/ml in viral supernatant freshly collected 
from plat E cells and supplemented with 10 µg/ml polybrene 
(EMD Millipore) and distributed at 1 ml/well in a 6-well plate 
and spin infected for 1 h at 2,800 rpm and 32°C. The cell su-
pernatant was then removed and replaced with conditioned 
medium. After 48 h, spin infection was repeated, and T cells 
were resuspended in complete medium containing 50% con-
ditioned medium. Bone marrow–derived macrophages were 
plated in 12- or 24-well plates (2–4 × 105 cells/well) for 20 h. 
Fresh viral supernatant collected from plat E cells and 10 µg/ml 
polybrene were added before spin infection for 1 h at 2,800 rpm 
and 32°C. The cell supernatant was then removed and replaced 
with fresh DMEM supplemented with 20% horse serum.
Bioassays
The cytopathic effect of mycolactone on HEK293-FRT 
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blue assay (Thermo Fisher Scientific). Its effect on secretory 
protein production was assessed with the Gaussia Glow-
Juice Luciferase kit (PJK GmbH) as follows. HEK293-FRT 
cell lines expressing WT Sec61α or R66G-Sec61α were 
grown on a 6-well plate and then transfected with a plas-
mid encoding a signal sequence-containing Gaussia lucif-
erase using Fugene 6 reagent (Promega). The expression of 
both the luciferase and Sec61α was induced 5  h later by 
addition of 1 µg/ml doxycycline. On the next day, 200,000 
cells/well were plated in 96-well plates and treated 5 h later 
with increasing concentrations of mycolactone. Luciferase 
activity in culture media was measured 24 h later with an 
EnSpire Multimode plate reader (PerkinElmer). Assays of 
mycolactone inhibition on cytokine production and hom-
ing receptors by mouse and human immune cells have 
been described previously (Boulkroun et al., 2010; Guenin-
Macé et al., 2011, 2015).
WaSP/n-WaSP and at2r silencing
siRNAs were ON-Target plus SMA RTpools (GE Health-
care) targeting human WASP (L-028294-00-0005), N-WASP 
(L-006444-00-0005), or AT2R (L-005429-00-005) or were 
nontargeting SMA RTpool (D0018101005) as controls. 107 
Jurkat T cells were electroporated twice at 48-h interval 
with 400 nM siRNA using the Gene Pulser Xcell system 
(Bio-Rad Laboratories) at 300 V and 500 µF. Silencing of 
WASP/N-WASP expression was optimal 24 h after the sec-
ond electroporation. HeLa cells were transfected with 10 nM 
siRNA using Lipofectamine RNAiMAX (Invitrogen). AT2R 
silencing was optimal 48 h after transfection.
Mouse studies
8-wk-old female mice (C57BL/6NCrl; Charles River) or 
congenic CD45.1 mice (B6.SJL-Ptprca Pepcb/BoyCrlPas; 
from our animal facilities) were housed under pathogen-free 
conditions with food and water ad libitum. The described ex-
periments received the approval of the French Ministry of 
Higher Education and Research. They were performed in 
compliance with national guidelines and regulations.
Statistical analysis
Two group comparisons used the Mann-Whitney rank test. 
Statistical analyses were performed with StatView 5 software 
(SAS Institute, Inc.), and values of P ≤ 0.05 were considered 
significant. Prism software (5.0d; GraphPad Software) was 
used for graphical representation.
online supplemental material
Fig. S1 shows chemical structures of all mycolactone and 
cotransin analogues used in this study, mapping of myco-
lactone-resistance mutations in a three-dimensional model 
of Sec61α structure, and IVT controls. Fig. S2 shows cyto-
toxicity of mycolactone and CT8 in human fibroblasts and 
T lymphocytes and effects of WASP/N-WASP and AT2R 
silencing on mycolactone-mediated inhibition of secretory 
protein production. Table S1 shows mycolactone-susceptible 
proteins in Jurkat T cells, as detected by our SIL AC analysis.
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